Literature DB >> 6401928

Treatment of ragweed allergic conjunctivitis with cromolyn sodium 4% ophthalmic solution.

G A Friday, A W Biglan, D A Hiles, S M Murphey, D L Miller, C Rothbach, S Rand.   

Abstract

We treated 31 patients with ragweed conjunctivitis in an eight-week, double-masked parallel-group study with cromolyn sodium 4% ophthalmic solution. Analysis of data showed preseason serum IgE antibody to ragweed level was a significant predictor of drug response. Of 16 patients with ragweed IgE values of less than 100 ng/ml, the nine treated with cromolyn had significantly fewer symptoms during the course of treatment than the seven in the placebo group. Of the 15 remaining patients, who had IgE levels of more than 100 ng/ml, the eight treated with cromolyn improved but the difference between their symptom scores and those of the seven patients treated with placebo was not statistically significant.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6401928     DOI: 10.1016/0002-9394(83)90010-7

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  5 in total

Review 1.  Ocular sodium cromoglycate. An overview of its therapeutic efficacy in allergic eye disease.

Authors:  E M Sorkin; A Ward
Journal:  Drugs       Date:  1986-02       Impact factor: 9.546

2.  Immunology of the eye--1983.

Authors:  B J Mondino
Journal:  Surv Immunol Res       Date:  1984

Review 3.  Therapeutic options in ocular allergic disease.

Authors:  M Hingorani; S Lightman
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

Review 4.  Treating the ocular component of allergic rhinoconjunctivitis and related eye disorders.

Authors:  Leonard Bielory; C H Katelaris; Susan Lightman; Robert M Naclerio
Journal:  MedGenMed       Date:  2007-08-15

Review 5.  Topical treatments for seasonal allergic conjunctivitis: systematic review and meta-analysis of efficacy and effectiveness.

Authors:  Christopher G Owen; Anupa Shah; Katherine Henshaw; Liam Smeeth; Aziz Sheikh
Journal:  Br J Gen Pract       Date:  2004-06       Impact factor: 5.386

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.